Willow Biosciences Third Quarter 2024 Earnings: CA$0.01 loss per share (vs CA$0.018 loss in 3Q 2023)
Willow Biosciences (TSE:WLLW) Third Quarter 2024 Results
Key Financial Results
- Revenue: CA$1.70m (up 153% from 3Q 2023).
- Net loss: CA$1.25m (loss narrowed by 44% from 3Q 2023).
- CA$0.01 loss per share (improved from CA$0.018 loss in 3Q 2023).
All figures shown in the chart above are for the trailing 12 month (TTM) period
Willow Biosciences shares are up 12% from a week ago.
Risk Analysis
We don't want to rain on the parade too much, but we did also find 4 warning signs for Willow Biosciences (2 are a bit unpleasant!) that you need to be mindful of.
Valuation is complex, but we're here to simplify it.
Discover if Willow Biosciences might be undervalued or overvalued with our detailed analysis, featuring fair value estimates, potential risks, dividends, insider trades, and its financial condition.
Access Free AnalysisHave feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
About TSX:WLLW
Willow Biosciences
A biotechnology company, develops, produces, and sells plant derived ingredients for consumer care, food and beverage, and pharmaceutical products in the United States.
Slight with imperfect balance sheet.